Technician 1 - Sequencing

Ultima Genomics doubles read output in $60 genome push. Ultima Genomics pairs higher sequencing output with workflow upgrades, while its $60 genome claim leaves labs to assess total costs and usable data quality. Key facts. * Platform update: Paired-end sequencing is now available on the UG200 Series. * Maximum output: Solaris 2.0 Max workflows deliver up to 20 billion reads per wafer. * Capacity comparison: Solaris 2.0 Max doubles the output of existing Solaris 2.0. * Cost claim: Ultima says the launch enables a $60 genome; the supplied details do not define all included costs. Ultima Genomics launched paired-end sequencing and Solaris 2.0 Max at ASHG 2026, with workflows delivering up to 20 billion reads per wafer and enabling what the company calls a $60 genome. Ultima Genomics is pairing a substantial increase in sequencing output with a change in how its instruments read DNA, linking the launch to a claimed $60 genome. The practical question for laboratories is whether those advances translate into cheaper, usable genetic information after the rest of the workflow is included. At ASHG 2026, the company launched paired-end sequencing on its UG200 Series and introduced Solaris 2.0 Max workflows. The latter deliver up to 20 billion reads per wafer, double the output of existing Solaris 2.0, according to the company announcement carried by PR Newswire Biotech. These are related but distinct developments. More reads can improve the economics of running a sequencing instrument. Paired-end sequencing can make the resulting data more useful and better suited to established analysis workflows. Neither improvement, by itself, establishes the total cost of delivering a finished genome analysis. Higher output changes the laboratory cost equation. A sequencing read is a measurement of a stretch of genetic material. Producing more reads from a wafer increases the amount of raw data available from that unit of processing. For laboratories with enough samples ready to run, that can create an opportunity to spread operating costs across more work. Ultima's stated maximum of 20 billion reads per wafer is therefore an important capacity measure. It is not, however, a count of completed genomes. How much sequencing a sample needs depends on the application, the desired depth of measurement and how much of the resulting data passes quality requirements. The phrase "up to" also matters. It describes the upper end of the announced output rather than a guaranteed result for every laboratory run. Buyers evaluating the upgrade will need to distinguish its stated capacity from the usable output they can reproduce with their own samples and procedures. Higher capacity is most valuable when a laboratory can keep it occupied. A facility with a steady flow of samples may be able to use the additional output efficiently. A smaller operation may instead face a choice between waiting to assemble a fuller run and processing samples sooner. That trade-off can affect both economics and turnaround time. Paired-end sequencing addresses usefulness, not just volume. Paired-end sequencing reads genetic fragments from both ends. The relationship between those readings can help analysis software place a fragment within a reference genome and interpret regions that are harder to resolve from a single reading direction. Ultima says the offering advances workflow compatibility and quality for germline whole genome sequencing and other applications. Germline analysis examines inherited genetic variation, rather than focusing solely on changes acquired in a particular tissue. In that setting, laboratories need reliable results across the genome, not simply a large volume of raw measurements. The compatibility element is commercially relevant because sequencing instruments do not operate in isolation. Laboratories prepare samples before sequencing, then use software and quality checks to turn the output into information researchers or clinicians can assess. A change in data format or characteristics can require adjustments throughout that process. The compatibility element is commercially relevant because sequencing instruments do not operate in isolation. Support for paired-end sequencing may make the platform easier to evaluate against workflows already built around that approach. But the supplied launch details do not quantify the improvement in accuracy or specify performance across different kinds of genetic variation. Those remain important questions for laboratories considering adoption. The $60 genome is not a complete laboratory bill. The headline cost claim is likely to draw attention because it offers a simple way to describe a technically complex product. Its usefulness depends on what is included. The available launch information says the technology enables a $60 genome, but does not provide a detailed accounting of that figure. A laboratory's full cost can include sample preparation, sequencing materials, instrument ownership, staff time, data storage and analysis. Additional review may be necessary depending on the intended use. Without a defined cost boundary, the announced figure should not be read as a universal price for a completed clinical test or interpreted genome. That distinction does not erase the potential significance of cheaper sequencing. If the sequencing component becomes less expensive while quality is maintained, research budgets could support broader sampling or more extensive measurement. The benefit would depend on whether other parts of the process can accommodate the additional work. Nor does doubling read output automatically mean halving the cost of every finished result. Some expenses vary with sample volume, while others depend on staffing, equipment or analysis requirements. The announcement establishes a higher output claim, not a proportional reduction in all laboratory spending. Adoption will depend on evidence beyond peak capacity. For prospective users, the most useful next step is an application-specific comparison. A laboratory studying inherited variation will want to know whether the new workflow produces the data quality its work requires, how consistently it performs and whether existing analysis tools can handle the output without extensive modification. Operational evidence matters alongside scientific performance. Laboratories will need to assess preparation requirements, run reliability, the frequency of repeat work and the computing resources needed to process larger data volumes. Savings at the sequencing stage can be diluted if downstream work becomes slower or more expensive. The launch does not establish a field-wide cost ranking. Comparing Ultima with other sequencing options would require matched assumptions about sample quality, sequencing depth, usable data and included expenses. A headline genome price alone cannot supply that comparison. Ultima's announcement nevertheless gives laboratories a concrete proposition to test: higher wafer output alongside paired-end data on the UG200 Series. The potential advance lies in combining volume with workflow usefulness. Whether that combination delivers the advertised economics will depend on reproducible performance and a clear accounting of what the $60 genome actually covers. Frequently asked questions. What did Ultima Genomics launch at ASHG 2026? Ultima Genomics launched paired-end sequencing on its UG200 Series and Solaris 2.0 Max workflows. The company says Solaris 2.0 Max delivers up to 20 billion reads per wafer, doubling existing Solaris 2.0 output. It also says the launch enables a $60 genome, without detailing the full cost calculation in the supplied information. What does paired-end sequencing do? Paired-end sequencing reads genetic fragments from both ends, giving analysis software related measurements that can help locate and interpret the fragments. Ultima says its offering advances workflow compatibility and quality for germline whole genome sequencing and other applications. The supplied announcement does not quantify the quality improvement across specific types of genetic variation. Does the $60 genome mean a complete genetic test costs $60? The supplied information does not establish that. Ultima says the launch enables a $60 genome, but does not define all included expenses. A completed test can involve sample preparation, staff time, instrument costs, storage, analysis and review. Laboratories need a clear cost breakdown before treating the figure as an all-inclusive test price. Does doubling read output double the number of completed genomes? Not necessarily. Ultima's output claim measures reads per wafer, rather than completed genome analyses. The number of samples a laboratory can process depends on required sequencing depth, usable data quality and the application. Higher raw output can expand capacity, but the announcement does not establish a universal count of finished genomes. Which laboratories could benefit from the higher output? Laboratories with enough samples to use the additional capacity could potentially spread sequencing expenses across more work. The benefit depends on sample volume, quality requirements and downstream resources. Smaller laboratories may need to balance fuller instrument runs against waiting time, while all users must assess whether their analysis systems can accommodate the output. What evidence should buyers examine before adopting the workflows? Buyers should examine usable data output, performance for their intended applications, workflow compatibility and the full cost of producing an acceptable result. Run reliability, repeat work and computing requirements also matter. Ultima's announced capacity and cost claims provide starting points for evaluation, but do not replace testing under a laboratory's own operating conditions.

Ultima launches paired-end sequencing and doubles output with Solaris Max. Ultima Genomics CEO Gilad Almogy says Solaris 2.0 Max can bring a 30x genome to $60, though the release does not define the costs included. By RuntimeWire Staff - Published Oct 20th, 2026, 9:54am CT - 4 MIN READ - 7 SOURCES - VIA PR Newswire Listen to article. Ultima Genomics launched commercial paired-end sequencing for its UG200 Series and made Solaris 2.0 Max consumables available on October 20th, according to its ASHG 2026 announcement... When you purchase through links in its articles, RuntimeWire, Inc. may earn a small commission. This doesn't affect its editorial independence. RuntimeWire, Inc. get virtually zero search traffic. Please consider sharing this story. Signal check Noise Signal Where does this story land? Drag the dial. The startup Ultima Genomics develops high-throughput sequencing platforms and workflows for genomics, proteomics, and single-cell applications. Ultima Genomics develops next-generation sequencing technology centered on its UG200 Series, with 20B, 10B, and 5B wafer output, up to 60 automated runs per week, and more than 60,000 genomes per year on the UG200 Ultra. The platform uses rapid isothermal amplification instead of ePCR and supports germline sequencing, oncology, single-cell sequencing, proteomics, epigenomics, and transcriptomics. Its ecosystem includes Solaris 2.0 library-prep workflows, pre-configured secondary analysis pipelines, a dedicated high-performance server for bioinformatics, and integrations or collaborations involving companies and tools such as 10x Genomics, Olink, AWS HealthOmics, Fabric Genomics, NVIDIA, Sentieon, and GATK. Customers and community references include UK Biobank, the Chan Zuckerberg Initiative, and Gene By Gene, whose Chief Scientific Officer describes running an UG 100 fleet in production with more than 100,000 whole-genome samples per month. Stay on the wire. Breaking startup & AI news, funding scoops, and launches as they happen. Follow @runtimewire on Threads and LinkedIn.